SecBot SecBot

GKOS drug pipeline

GLAUKOS Corp · 3 rated drugs
$244.88
−0.3% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±6.9%
1-day, median of 3 events
IV rank
No data
No current options data
Rated drugs
3
3 neutral
Phase 3 trials
1
1 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 2b/3
Time to marketUnknown; Phase 2b/3 trials typically take 2-4 years to complete, so potential approval would likely be 2028-2030 at earliest, assuming positive data.

iDose TREX travoprost intracameral implant Updated Aug 27

What to watch

Monitor for interim or topline data readouts from the Phase 2b/3 program, which could serve as a catalyst. The next meaningful update may come at a major ophthalmology conference. Meanwhile, iDose TR commercial adoption trends and quarterly earnings are the primary near-term drivers for GKOS stock.

Bull case
  • iDose TREX has nearly double the drug capacity of the already-approved iDose TR, potentially offering longer-lasting IOP control and a competitive advantage in the glaucoma implant market.
  • The first-generation iDose TR is already FDA-approved and commercially launched, providing a clinical and regulatory de-risking pathway for iDose TREX.
  • Analyst consensus is Strong Buy (18 buy/strong buy vs 2 hold and 1 sell) with a mean price target of $197.15, implying ~8% upside from the current ~$180.57 price.
Bear case
  • iDose TREX is still in Phase 2b/3 with no specific topline readout date announced, meaning a potential approval is likely years away (2028-2030 at earliest).
  • Multiple insiders (President & COO, directors) have been selling shares in recent months, with transactions totaling over $1M at prices around $150-190.
  • Short interest stands at ~6.70% of outstanding shares (5.21 days to cover), indicating some bearish positioning.
● neutral
Impact
PhaseApproved
Time to marketAlready on market since 2016

Photrexa riboflavin 5'-phosphate ophthalmic solution Updated Aug 27

What to watch

Photrexa itself has no upcoming binary catalyst, it is an approved, marketed legacy product. Investors should instead focus on Glaukos's next-generation Epioxa (epi-on CXL, approved Oct 2025) and iDose TR glaucoma platform as the primary growth drivers. Monitor quarterly earnings for Epioxa adoption trends and the company's $690M 2026 revenue guidance execution.

Bull case
  • Photrexa is the first-and-only FDA-approved corneal cross-linking therapy for keratoconus, with orphan drug exclusivity and a well-established market position since 2016
  • Glaukos has strong financials: $289M cash with no debt, 85% non-GAAP gross margins, and 20% 10-year revenue CAGR
  • Analyst consensus is strongly bullish on GKOS, 18 Buy/Strong Buy ratings vs. only 1 Sell, with a mean price target of $197 (8% upside from $180.57)
Bear case
  • Epioxa (approved Oct 2025) is a less-invasive 'epi-on' version that may cannibalize Photrexa sales as surgeons and patients migrate to the newer technology
  • Photrexa requires epithelium removal (epi-off), which is more invasive and uncomfortable for patients compared to the newer epi-on alternatives
  • The drug has been on market since 2016 with no new label expansion or regulatory catalyst ahead, making it a mature product with limited growth potential
● neutral
Impact
PhaseNot found
Time to marketNot estimable - drug candidate not identified.

GLK-901 Updated Oct 28

What to watch

GLK-901 could not be verified as a Glaukos drug candidate through any public source. Investors should treat this name with extreme caution and seek clarification from the company before assuming it represents a real development program. Glaukos's confirmed pipeline includes GLK-321 (Phase 2, Demodex blepharitis), GLK-401 (Phase 2, retinal diseases), and GLK-601 (Phase 2, corneal epithelial defects), among others.

Bull case
  • Not applicable - GLK-901 could not be confirmed as a Glaukos drug candidate.
Bear case
  • GLK-901 does not appear in any public Glaukos pipeline, SEC filing, clinical trial registry, press release, or investor presentation, suggesting it may not be a real development asset or may be a very early preclinical candidate not yet disclosed.
  • The only web results for 'GLK-901' are for a dishwashing detergent product, creating potential confusion for investors searching for this name.

Other drugs in filings and trials

no drug report yet
  • EPIOXA HD/EPIOXA KIT Last: Approval · Oct 17, 2025
  • IDOSE TR Last: Approval · Dec 13, 2023
  • PHOTREXA VISCOUS IN DEXTRAN 20% Last: Approval · Apr 15, 2016
  • Riboflavin 1 trial

Past FDA events & how the stock moved

3 events
DateDrugEvent1 day5 days
Oct 17, 2025EPIOXA HD/EPIOXA KITApproval−6.9%−12.5%
Dec 13, 2023IDOSE TRApproval+21.3%+27.5%
Apr 15, 2016PHOTREXA VISCOUS IN DEXTRAN 20%Approval+4.8%+1.2%

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
RiboflavinSafety and Effectiveness Study of the VEGA UV-A System for Cross-linking in Eyes With Keratoconus and EctasiaPhase 3Terminated · results—Not stated